Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 4/20 | 0.36 |
| ▸ | BCHE | P06276 | 3/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1692503 | 0.81 | MPO (0.40) | ALDH1A1CYP1A2ACHEHRH4 | |
| SCHEMBL29892219 | 0.78 | CYP1A2 (0.41) | GRM2ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL17250761 | 0.77 | ALDH1A1 (0.49) | ALDH1A1MAPTLMNAPLA2G1BL3MBTL1 | |
| SCHEMBL164991 | 0.76 | GRM2 (0.41) | GRM2ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL27846129 | 0.76 | GRM2 (0.43) | GRM2ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL13975885 | 0.75 | HRH4 (0.51) | GRM2ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL20793006 | 0.74 | NQO2 (0.41) | GRM2ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL6593684 | 0.74 | CYP1A2 (0.50) | GRM2ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL161614 | 0.72 | GRM2 (0.36) | GRM2ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL15978468 | 0.71 | TRPA1 (0.41) | GRM2ALDH1A1MAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8734777-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130209397-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-8329712-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120009144-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130209397-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, MAVS | GRM2 4819/4885ALDH1A1 540/4885MAPT 4663/4885 |
| US-20120009144-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RNASE1 | GRM2 4806/4885ALDH1A1 466/4885MAPT 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.